Patent ID: 7585493

Claim:
An article for use in an aerosol device, for producing an aerosol, comprising a heat conductive substrate having a surface with a surface area, and a film comprising a drug composition on the surface, the film having a film thickness, wherein the drug composition and film thickness are selected from the group consisting of the following combinations: alprazolam, film thickness between 0.1 and 10 μm; amoxapine, thickness between 2 and 20 μm; apomorphine HCl, film thickness between 0.1 and 5 μm; atropine, film thickness between 0.1 and 10 μm; budesonide, film thickness between 0.05 and 20 μm; bumetanide film thickness between 0.1 and 5 μm; buprenorphine, film thickness between 0.05 and 10 μm; butorphanol, film thickness between 0.1 and 10 μm; celecoxib, film thickness between 2 and 20 μm; chlorpheniramine, film thickness between 0.05 and 20 μm; ciclesonide, film thickness between 0.05 and 5 μm; clomipramine, film thickness between 1 and 8 μm; diazepam, film thickness between 0.05 and 20 μm; diphenhydramine, film thickness between 0.05 and 20 μm; donepezil, film thickness between 1 and 10 μm; eletriptan, film thickness between 0.2 and 20 μm; fentanyl, film thickness between 0.05 and 5 μm; granisetron, film thickness between 0.05 and 20 μm; hydromorphone, film thickness between 0.05 and 10 μm; lorazepam, film thickness between 0.05 and 20 μm; loxapine, film thickness between 1 and 20 μm; midazolam, film thickness between 0.05 and 20 μm; morphine, film thickness between 0.2 and 10 μm; nalbuphine, film thickness between 0.2 and 5 μm; naratriptan, film thickness between 0.2 and 5 μm; olanzapine, film thickness between 1 and 20 μm; parecoxib, film thickness between 0.5 and 2 μm; paroxetine, film thickness between 1 and 20 μm; prochlorperazine, film thickness between 0.1 and 20 μm; quetiapine, film thickness between 1 and 20 μm; ropinirole, film thickness between 0.05 and 20 μm; sertraline, film thickness between 1 and 20 μm; sibutramine, film thickness between 0.5 and 2 μm; sildenafil, film thickness between 0.2 and 3 μm; sumatriptan, film thickness between 0.2 and 6 μm; tadalafil, film thickness between 0.2 and 5 μm; valdecoxib, film thickness between 0.5 and 10 μm; and vardenafil, film thickness between 0.1 and 2 μm; venlafaxine, film thickness between 2 and 20 μm; zaleplon, film thickness between 0.05 and 20 μm; and zolpidem, film thickness between 0.1 and 10 μm; wherein an aerosol formed by vaporizing the drug composition by heating the substrate and condensing the vaporized drug composition contains 10% by weight or less drug degradation products and at least 50% of the total amount of drug composition in the film, and wherein the substrate surface area is such as to yield an effective human therapeutic dose of the drug aerosol.